Cure8 research brief
The findings give clinicians and patients data on how often biologic therapy leads to endoscopic remission in biologic‑naïve patients with isolated small‑bowel Crohn's disease, and they suggest similar effectiveness between infliximab and ustekinumab after matching.
Clinicians treating small‑bowel Crohn's disease, researchers studying biologic effectiveness in isolated SB‑CD, and adult patients considering biologic therapy (especially biologic‑naïve patients).
The study included 169 biologic‑naïve patients with isolated SB‑CD who started IFX (n=122) or UST (n=47) and had follow-up double‑balloon enteroscopy. ER was defined as SES‑CD <3. Overall ER was 35.5% (32.8% IFX, 42.6% UST).
Multivariate analysis found that stricturing/penetrating disease and moderate-to-severe endoscopic activity were associated with lower odds of ER. After propensity matching, IFX and UST showed no significant differences in endoscopic response, ER, mucosal healing, clinical remission, or biochemical remission.
Results come from a retrospective single‑center cohort with double‑balloon enteroscopy follow-up; abstract-level data do not substitute for randomized trials. The study timeframe was 2020–2025 and used SES‑CD <3 to define endoscopic remission.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
The study is comparing common biologics given after Crohn's surgery to prevent endoscopic recurrence—a key issue for people who have had bowel resection. Knowing which drugs perform better in real‑world practice could...
Patients, families, and clinicians can use registry-based predictors to better understand which children with Crohn’s disease may be at higher risk of slower or absent remission, which could inform monitoring and...
The study suggests blood metabolite patterns differ by biologic therapy and identifies candidate biomarkers that might help develop less-invasive monitoring tools for inflammation and treatment effects in Crohn’s...
